Three cardiology trials came to a conclusion
Three large randomized cardiology trials came to a conclusion recently: the GLOBAL LEADERS, MATRIX and Bioscience Orsiro trials. CTU Bern was involved in all three trials.
The GLOBAL LEADERS trial randomized 16000 patients eligible for percutaneous coronary stenting to an experimental antiplatelet medical strategy of 24 months Ticagrelor with one month of Aspirin only, versus the control antiplatelet medical strategy of 12 months of standard DAPT regimen followed by another 12 months of Aspirin only. The primary outcome of the composite of all-cause mortality or new Q-wave myocardial infarction or equivalent LBBB did not differ between both arms. See https://www.youtube.com/watch?v=FtV9Q9wvMvM for more information and the Lancet for the publication. The other two trials MATRIX and Bioscience Orsiro already published their primary outcomes at 30 days and 1 year follow-up earlier, and now followed the prolonged follow-up analyses at 1 year and 5 years, respectively. Both trials were also published in the Lancet. See for more information e.g. https://www.youtube.com/watch?v=0s5rXJ_7J6k and https://cardiovascularnews.com/esc-2018-higher-all-cause-mortality-with-orsiro-at-five-years-than-with-xience/